BTCY vs. ICAD, MODD, GBS, AKLI, CODX, RVP, IINN, MDAI, TTOO, and ICU
Should you be buying Biotricity stock or one of its competitors? The main competitors of Biotricity include iCAD (ICAD), Modular Medical (MODD), GBS (GBS), Akili (AKLI), Co-Diagnostics (CODX), Retractable Technologies (RVP), Inspira Technologies Oxy B.H.N. (IINN), Spectral AI (MDAI), T2 Biosystems (TTOO), and SeaStar Medical (ICU). These companies are all part of the "surgical & medical instruments" industry.
Biotricity (NASDAQ:BTCY) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.
iCAD has higher revenue and earnings than Biotricity. iCAD is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.
iCAD received 228 more outperform votes than Biotricity when rated by MarketBeat users. Likewise, 62.81% of users gave iCAD an outperform vote while only 0.00% of users gave Biotricity an outperform vote.
Biotricity has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, iCAD has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
iCAD has a consensus target price of $5.00, suggesting a potential upside of 244.83%. Given iCAD's higher probable upside, analysts clearly believe iCAD is more favorable than Biotricity.
iCAD has a net margin of -15.20% compared to Biotricity's net margin of -125.43%. Biotricity's return on equity of 0.00% beat iCAD's return on equity.
In the previous week, iCAD had 2 more articles in the media than Biotricity. MarketBeat recorded 3 mentions for iCAD and 1 mentions for Biotricity. Biotricity's average media sentiment score of 1.89 beat iCAD's score of 0.96 indicating that Biotricity is being referred to more favorably in the media.
3.9% of Biotricity shares are held by institutional investors. Comparatively, 24.6% of iCAD shares are held by institutional investors. 20.5% of Biotricity shares are held by insiders. Comparatively, 12.0% of iCAD shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
iCAD beats Biotricity on 11 of the 16 factors compared between the two stocks.
Get Biotricity News Delivered to You Automatically
Sign up to receive the latest news and ratings for BTCY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BTCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biotricity Competitors List
Related Companies and Tools
